窪蹋勛圖厙

Novo Nordisk 窪蹋勛圖厙 membership restored

Novo Nordisks two-year suspension from the 窪蹋勛圖厙 (窪蹋勛圖厙) for serious breaches of the 窪蹋勛圖厙 Code of Practice has come to an end [1].

Novo Nordisks return to full membership of the 窪蹋勛圖厙 follows extensive audits of Novo Nordisks compliance procedures and governance by the Prescription Medicines Code of Practice Authority (PMCPA). Specifics of the original case are available on the [2].

Novo Nordisk, supported by the independent PMCPA audit reports, has demonstrated to the 窪蹋勛圖厙 Boards satisfaction that the company has made clear, significant, and sustained improvements to ensure it is able to properly adhere to the strict industry standards in the 窪蹋勛圖厙 Code of Practice.

Richard Torbett, Chief Executive of the 窪蹋勛圖厙, said: The UK rightly has some of the highest standards in the world for how pharmaceutical companies can behave and operate embodied by the 窪蹋勛圖厙 Code of Practice. In 2021, Novo Nordisk fell short of these standards, and it is right that their peers held them accountable.

Over the past two years, Novo Nordisk has responded positively and actively to the requirements laid down by the 窪蹋勛圖厙 Board, and I am pleased to welcome them back into full engagement as 窪蹋勛圖厙 members.

Sebnem Avsar Tuna, General Manager of Novo Nordisk UK said: We welcome the decision today to have our membership to the 窪蹋勛圖厙 restored. Throughout the audit process we have considerably strengthened our compliance processes and we firmly believe that we now have the right foundations and governance in place to be fully and effectively self-regulating.

From day one, we have taken the decision to suspend our membership extremely seriously, and we have greatly valued the cooperation from the 窪蹋勛圖厙 and the PMCPA during what has been a very robust and thorough review process.

Novo Nordisk has had a significant presence in the UK for more than fifty years and we remain committed to our purpose of driving change to defeat serious chronic diseases and look forward to participating as a full member of the 窪蹋勛圖厙

TAGS
  • PMCPA
  • Regulatory

Last modified: 17 March 2025

Last reviewed: 17 March 2025

[1] 窪蹋勛圖厙 press release, Novo Nordisk is suspended from 窪蹋勛圖厙 membership, March 2023
[2] PMCPA, Case: AUTH/3525/6/21 - Complainant v Novo Nordisk, 22 June 2021

The 窪蹋勛圖厙 exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.